In an analysis of 3 placebo‐controlled, randomized, Phase 3 studies of a selective SGLT2 inhibitor, researchers observed clinically meaningful decreases in glycated HbA1c, fasting plasma glucose, and more...
Findings from a retrospective new-user cohort study of female Medicare beneficiaries aged 65 years or older shed light on whether insulin glargine use is associated with increased breast cancer risk...
In a randomized controlled trial, researchers investigated whether this sodium-glucose cotransporter 2 inhibitor could reduce liver fat content among patients with recent-onset and metabolically...
In a recent systematic review and meta-analysis, researchers compared the effects of SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 agonists, and other antidiabetic agents in improving left ventricular...
In a recent study, researchers tested the efficacy of hemoglobin A1c testing in black barbershops in identifying undiagnosed diabetes and prediabetes among black men in Brooklyn, New York.
The US Food and Drug Administration has approved the first and only fast-acting mealtime insulin injection that does not have a pre-dosing recommendation for use in children with diabetes.
